Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis In Vivo Efruxifermin (0-100 mg/kg, SC, Once weekly, for 4 or 26 weeks) reduces body weight gain of Sprague Dawley rats in a dose-dependent manner . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male and female Sprague Dawley rats Dosage: 0, 1, 10, 30, 100 mg/kg Administration: Subcutaneous injection, Once weekly, for 4 or 26 weeks Result: Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged. IC50& Target:FGF21
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Efruxifermin
CAS number：2375240-92-7 molecular formula：
overview
compound introduction
Specs
| Chinese alias | 依夫昔芬 | ||
| English alias | - | ||
| CAS number | 2375240-92-7 | molecular formula | |
| molecular weight | - | Exact mass | - |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
